Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IOX vs FLOX in Advanced Gastric Cancer
NCT00447967Phase 2Completed
- Sponsor
- Hellenic Oncology Research Group
- Start
- Jul 2004
- Primary completion
- Sep 2008
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab in gastric cancer (GC) (2 arms), sponsored by Hellenic Oncology Research Group. Primary endpoint: Objective Response Rates. Started Jul 2004; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab
03
Conditions
gastric cancer (GC)
Beyond the preview
Go deeper on NCT00447967.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00447967.